

SHREE GANESH BIO-TECH (INDIA) LIMITED

CIN: L70101WB1982PLC121196

Reg. Office: CUBICLE NO.: 126, 3/2, 75C, PARK STREET, 3RD FLOOR KAMDHENU BUILDING, KOLKATA -700016

Email: shreeganeshbiotechindia ltd@gmail.com Website: www.shreeganeshbiotech. shop

Date: 29.01.2026

To,
Listing Department,
BSE Limited, .
P J Tower, Dalal Street
Mumbai-400001

To,
The Secretary,
The Calcutta Stock Exchange Ltd,
7, Lyons Range,
Kolkata - 700001

To,
Head - Listing
Metropolitan Stock
Exchange of India Limited
Vibgyor Towers, 4th floor,
Plot Noe 62, Opp. Trident
Hotel Bandra Kurla Complex,
Bandra (E)
Mumbai - 400098

Scrip Code: 539470

Scrip Code: 29221

Scrip Code-SHREEGANES

Sub: Outcome of the Board Meeting of the board held on 29th January 2026.

Ref: Regulations 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. **Thursday 29th January 2026** at the Registered Office of the Company and transacted the following major businesses:

1.) Considered and approved Un-audited financial results for the quarter and nine months ended as on **31st December, 2025.**

The board meeting commenced at **03:30 PM and concluded at 04:00 PM**

Please take the above intimation in your records.

Thanking You.

FOR , SHREE GANESH BIO-TECH (INDIA)LIMITED

**AMAN PATEL
WHOLETIME DIRECTOR**

Shree Ganesh Biotech (India) Limited

CIN: L70101WB1982PLC121196

Reg. Office Address: 126, 3/2, 75C, Park Street, 3rd Floor, Kamdhenu Building, Kolkata - 700016

Email : shreeganeshbiotechindia@gmail.com

Statement of Standalone Financial Results for the quarter ended on December 31, 2025

Particulars		Quarter Ended			Nine Months Ended		
		31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	Year Ended
A	Date of start of reporting period	01-10-2025	01-07-2025	01-10-2024	01-04-2025	01-04-2024	01-04-2024
B	Date of end of reporting period	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	31-03-2025
C	Whether results are audited or unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
D	Nature of report standalone or consolidated	Standalone	Standalone	Standalone	Standalone	Standalone	Standalone
I	Revenue From Operations						
	Net sales or Revenue from Operations	69.81	76.74	1,441.18	284.92	1,995.18	2,295.76
II	Other Income	37.08	41.01	30.43	119.63	97.58	144.09
III	Total Income (I+II)	106.90	117.75	1471.60	404.54	2092.76	2439.85
IV	Expenses						
(a)	Cost of materials consumed	66.08	111.75	1,375.91	289.81	1,911.65	2,264.10
(b)	Purchases of stock-in-trade	-	-	-	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-	-	-
(d)	Employee benefit expense	7.35	3.35	6.23	12.13	8.51	9.76
(e)	Finance Costs	-	-	-	-	-	-
(f)	Depreciation and amortisation expense	-	-	-	-	-	0.05
(g)	Other Expenses	1.24	1.24	12.29	36.27	39.31	127.25
	Total expenses (IV)	74.67	116.34	1394.43	338.20	1959.47	2401.16
V	Profit/(loss) before exceptional items and tax (III-IV)	32.23	1.41	77.17	66.34	133.29	38.69
VI	Exceptional items	-	-	-	-	-	-
VII	Profit (loss) after exceptional items and before Tax (V-VI)	32.23	1.41	77.17	66.34	133.29	38.69
VIII	Tax Expense	-	-	-	-	-	10.85
(a)	Current Tax	-	-	-	-	-	10.85
(b)	(Less):- MAT Credit	-	-	-	-	-	-
(c)	Current Tax Expense Relating to Prior years	-	-	-	-	-	-
(d)	Deferred Tax (Asset)/Liabilities	-	-	-	-	-	-
IX	Profit (Loss) after Tax for the period (VII-VIII)	32.23	1.41	77.17	66.34	133.29	27.84
X	Other Comprehensive Income						
	a. i). Items that will not be reclassified to profit or loss	-	-	-	-	-	-
	ii). Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-	-	-
	b. i). Item that will be reclassified to profit or loss	-	-	-	-	-	-
	ii). Income tax relating to items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total Comprehensive income	0.00	0.00	0.00	0.00	0.00	0.00
XI	Total Comprehensive income [Comprising Profit for the Period and Other comprehensive income] (XIV+XV)	32.23	1.41	77.17	66.34	133.29	27.84
XII	Details of equity share capital						
	Paid-up equity share capital	3,986.24	3,986.24	3,986.24	3,986.24	3,986.24	3,986.24
	Face value of equity share capital (Per Share)	1.00	1.00	1.00	1.00	1.00	1.00
XIII	Other Equity	-	-	-	-	-	2339.35
XIV	Earnings per share						
(a)	Earnings per share (not annualised for quarter ended)						
	Basic earnings (loss) per share from continuing operation	0.01	0.00	0.02	0.02	0.03	0.01
	Diluted earnings (loss) per share from continuing operation	0.01	0.00	0.02	0.02	0.03	0.01

Notes on Financial Results:-

- The above unaudited standalone financial results for the quarter ended December 31, 2025 have been reviewed by the Audit Committee and subsequently approved by the Board of Directors in their respective meetings held on January 29, 2026. The statutory auditors have carried out limited review of above result.
- The unaudited standalone financial results are prepared in accordance with the Indian Accounting Standards 34 "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) (Amendment Rules), 2016.
- As per Indian Accounting Standard 108 on 'Operating Segment' (Ind AS 108), the company has only one reportable segment.
- The figures for the corresponding previous period have been restated/regrouped wherever necessary, to make them comparable.
- Provision for Taxation if any will be made at year end.

For, Shree Ganesh Biotech (India) Limited

Date :- 29th January, 2026
Place:- Kolkata

Aman Patel
Wholetime Director
DIN: 08483544



Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To
The Board of Directors of
SHREE GANESH BIO-TECH (INDIA) LIMITED
KOLKATA

We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of SHREE GANESH BIO-TECH (INDIA) LIMITED ("the Company") including notes there on, for the Quarter ended on December 31, 2025 and year to date results for the period from 01 April, 2025 to 31 December, 2025 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards " (Ind AS 34)" "Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 as amended, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and

measurement principles laid down in the aforesaid Indian Accounting Standards (Ind AS) and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For, Bipin & Co.
Chartered Accountants
FRN: 101509 W



CA Amit Shah
Partner
M. No.: 126337
Place: Vadodara
Date: 29.01.2026
UDIN: 26126337CCARKT1134

